C4 Therapeutics, Inc. (NASDAQ:CCCC) Holdings Raised by Soleus Capital Management L.P.

Soleus Capital Management L.P. increased its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 6,978,942 shares of the company's stock after acquiring an additional 374,946 shares during the period. C4 Therapeutics makes up approximately 1.6% of Soleus Capital Management L.P.'s holdings, making the stock its 20th largest holding. Soleus Capital Management L.P. owned about 9.89% of C4 Therapeutics worth $25,124,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers lifted its position in C4 Therapeutics by 4.6% during the 4th quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock worth $360,000 after acquiring an additional 4,366 shares in the last quarter. Sei Investments Co. acquired a new position in C4 Therapeutics during the 4th quarter worth approximately $45,000. American Century Companies Inc. lifted its position in C4 Therapeutics by 8.5% during the 4th quarter. American Century Companies Inc. now owns 132,832 shares of the company's stock worth $478,000 after acquiring an additional 10,459 shares in the last quarter. Geode Capital Management LLC lifted its position in C4 Therapeutics by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,381,086 shares of the company's stock worth $4,973,000 after acquiring an additional 11,410 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in C4 Therapeutics by 115.4% during the 4th quarter. Balyasny Asset Management L.P. now owns 42,533 shares of the company's stock worth $153,000 after acquiring an additional 22,789 shares in the last quarter. 78.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, UBS Group raised C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th.

C4 Therapeutics Stock Up 0.7%

Shares of CCCC traded up $0.01 during trading on Friday, reaching $1.38. The company's stock had a trading volume of 453,269 shares, compared to its average volume of 1,390,303. The company has a fifty day moving average of $1.52 and a two-hundred day moving average of $2.95. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $7.66. The company has a market cap of $97.99 million, a price-to-earnings ratio of -0.81 and a beta of 3.10.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $3.54 million. As a group, equities analysts forecast that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.